Methods: Patients with Child-Pugh (CP) score 7 were treated with 400 mg twice daily of sorafenib with escalating doses of selumetinib in a 3 þ 3 study design. The dose-limiting toxicity (DLT) evaluation period was 28 days. PK of selumetinib was determined. Angiogenic effect was evaluated with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).
Results: Twenty-seven patients of Asian ethnicity were enrolled. The MTD was selumetinib 75 mg daily with sorafenib 400 mg twice daily. DLT included grade 3 transaminitis, diarrhoea and fatigue. Most common treatment-related adverse events at MTD (all grades) were diarrhoea (85%), rash (59%), hypertension (44%), fatigue (30%), anorexia (22%) and hand-foot syndrome (22%). Four patients (15%) had PR and 13 (48%) had SD. PR or SD was observed for !6 months in seven patients. The median overall survival was 14.4 months. Selumetinib exposures in combination with sorafenib were comparable to other monotherapy studies. A reduction in permeability-surface area product noted in DCE-MRI with treatment correlated with worse survival outcomes.
Conclusion:
The MTD of selumetinib was 75 mg daily when combined with sorafenib 400 mg twice a day in CP 7 HCC. Acceptable adverse events and encouraging anti-tumour activity warrant further evaluation. DCE-MRI findings deserve prospective evaluation.
ClinicalTrials.gov identifier: NCT01029418.
Key words: hepatocellular carcinoma, selumetinib (AZD6244, ARRY-142886), sorafenib, pharmacokinetics introduction Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and second leading cause of cancer mortality [1] . About 80% of patients with HCC present with advanced disease where treatment with sorafenib led to improvement in median overall survival (mOS) compared with placebo [2] .
Activation of MAPK pathway has been demonstrated in the majority of HCC [3, 4] . This is attributed to autocrine/paracrine signalling through receptor tyrosine kinase and decreased expression of RAS pathway inhibitors [5] [6] [7] . Combination of sorafenib and selumetinib (AZD6244, ARRY-142886), an oral, potent and highly selective, allosteric MEK1/2 inhibitor led to enhanced antitumour activity in patient-derived HCC xenografts compared with either agent alone. Treatment with sorafenib led to up-regulation of pERK. The addition of selumetinib to sorafenib resulted in abrogation of pERK activity and greater antitumor effect [8] .
We report the results of phase Ib trial of selumetinib in combination with sorafenib in patients with advanced HCC. The primary objective of the study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT). Secondary objectives were to determine the pharmacokinetics of selumetinib when combined with sorafenib and efficacy. The impact of this combination on angiogenesis was explored with dynamic contrastenhanced magnetic resonance imaging (DCE-MRI).
methods inclusion criteria
Eligible patients had histology-proven treatment-naïve Barcelona Clinic Liver Cancer (BCLC) stage B/C HCC. Inclusion criteria included Child-Pugh (CP) scores of A or B (7 only), Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1; life expectancy !3 months; and adequate organ function. Prior local therapy was allowed if carried out !4 weeks before study commencement. Anti-viral therapy was mandatory for patients with underlying hepatitis B infection.
The institutional review board approved this trial. All patients provided written informed consent. This trial was registered on ClinicalTrials.gov (NCT01029418).
study design and dosing
Sorafenib was administered at a fixed dose of 400 mg twice daily (bid), while dose of selumetinb was escalated according to a schedule starting at 75 mg daily (od) [dose level (DL) 0]. At DL 1, selumetinib was 50 mg bid and at DL 1A, 100 mg od. Both drugs were administered orally. Sorafenib monotherapy was given in a 1-week lead in period followed by combination of sorafenib and selumetinib. Sorafenib was given first as we wanted to explore its anti-angiogenic effects via DCE-MRI before addition of AZD6244. Each cycle consisted of 28 days.
The standard '3 þ 3' rule was employed for dose escalation. The MTD was defined as the highest dose at which DLT was experienced by <33% patients (DLT 1/6 patients).
An additional 15 patients were accrued at MTD forming the expansion cohort. DLT was defined as any of the following, during the first 28 days of combination therapy: (i) haematological toxicities-afebrile grade 4 neutropenia >5 days or grade 4 neutropenia with fever, grade 4 thrombocytopenia, inability to resume dosing within 14 days of drug interruption, (ii) non-haematological toxicities-!grade 3 non-haematological toxicities for >7 days.
response assessment and safety assessment A designated radiologist conducted tumour assessments using RECIST version 1.1. CT or MRI scans, echocardiography and 45-item-FACT-HEP questionnaires were conducted at baseline and every 8 weeks. Physical examination, laboratory analyses and assessment of adverse events according to NCI CTCAE v 3 were done at baseline, week 2 and before each new cycle. A complete ophthalmology examination was carried out at regular intervals by an assigned ophthalmologist.
pharmacokinetic studies
Blood samples for selumetinib, selumetinib amide and N-desmethyl selumetinib concentrations were taken from patients on day 10 at the following time points: 0, 0.5, 1, 2, 4, 8 and 24 h; and at trough on day 1 of cycle 2 and 3. Area under the concentration-time curve (AUC), maximum concentration (C max ) and time to maximum concentration (T max ) were determined using non-compartmental methods. Oral clearance, half-life, steadystate volumes of distribution were also calculated.
fluorescence-activated cell sorting analysis on peripheral blood mononuclear cells
Systemic MEK-, MTOR-and VEGF-inhibition effects of the test drugs were investigated by fluorescence-activated cell sorting (FACS) analysis to assess modulations in the percentage of phosphorylated-ERK (pERK) and the frequencies of both circulating endothelial (CEC: [10, 11] in the peripheral blood mononuclear cell (PBMC) collected at baseline and day 28 of treatment.
KRAS determination
EntroGen K-RAS Mutation Analysis Kit using allele-specific real-time PCR was carried out on tumour specimens. This test detects 11 KRAS mutations in codons 12, 13 and 61 of the KRAS oncogene.
DCE-MRI imaging
DCE-MRI was carried out at baseline, day 7 (effect from sorafenib monotherapy) and day 14 (combination sorafenib and selumetinib). DCE-MRI scans were carried out this way to study the effects of sorafenib alone and in combination on angiogenesis, thus as a potential biomarker. Details of the technique were previously published [12] .
statistical analysis
Patients with measurable disease by RECIST who completed one scan after treatment or discontinued for clinical progression were included in the response analyses. 95% confidence intervals for overall response rate (RR) and disease control rate (DCR) were estimated using the exact method. The median progression-free survival (mPFS) and mOS were estimated using Kaplan-Meier.
The ratio of the baseline and day 28 MEK-, MTOR-and VEGF-inhibition effects was determined. Log-transformed differences were tested using the one-sample Wilcoxon signed-rank test.
Fold-changes for DCE-MRI parameters were derived by the ratio of day 7/14 and baseline value. The association between fold changes and PFS/OS was analysed as covariates in the Cox regression. The relationship between DCE-MRI parameters and best overall response (CR þ PR þ SD versus PD) was assessed using logistic regression.
results patient characteristics
From March 2010 to February 2013, 27 patients were enrolled into this study. Clinical characteristics of the patients are summarised in Table 1 . There were 24 males (88.9%) and 3 females (11.1%) with a median age of 63 (range 43-74). The majority (63%) of patients had ECOG PS 0. Twenty-six (96.3%) patients had underlying CP A and 16 (59.3%) had underlying hepatitis B infection. The majority of patients had BCLC Stage C (74.1%) and 48.1% had extra-hepatic disease. Nineteen (70.3%) patients had elevated a-fetoprotein (AFP) level at study entry.
drug administration and DLs
Twenty-seven patients enrolled into the study: 18 at DL 0 (sorafenib 400 mg bid þ selumetinib 75 mg od) 6 at DL I (sorafenib 400 mg bid þ selumetinib 50 mg bid) and 3 at DL IA (sorafenib 400 mg bid þ selumetinib 100 mg od). Three patients enrolled into DL 0 with no DLT seen. Two DLTs were seen out of six patients at DL I (selumetinib at 50 mg bid): grade 3 fatigue, and grade 3 abdominal pain with elevated transaminases. An exploratory cohort of selumetinib 100 mg od was evaluated in view of emerging data from phase I combination study of selumetinib and MK2206. Interestingly, selumetinib at 100 mg od when combined with MK2206 yielded lower toxicities compared with selumetinib at 50 mg bid. pERK was robustly suppressed at exposure levels of 100 mg od [13] . Two out of three patients had DLT at DL IA: grade 3 raised aspartate transaminase and grade 3 diarrhoea. Thus, the MTD was determined to be selumetinib at 75 mg od when combined with sorafenib 400 mg bid (DL 0). A further 15 patients were enrolled. 
pharmacokinetics of selumetinib
All 27 patients were assessed for pharmacokinetics of selumetinib and its active metabolite N-desmethyl selumetinib. Selumetinib was absorbed relatively quickly across all DLs, with T max reached in 2 h (Table 3 ). The median t 1/2 and CL/F of selumetinib were 5.3 h and 11.9 l/h, respectively. The mean AUC (0-24) increased in proportion to dose over the range of doses studied, with no evidence of saturation of drug absorption. The pharmacokinetic profile of plasma N-desmethyl selumetinib was similar to selumetinib evidenced by close T max and t 1/2 values, although its exposure was much lower than parental compound. The AUC ratio of plasma selumetinib to N-desmethyl selumetinib was <12%-for all three cohorts (Table 3) .
FACS on PBMC
Only 9 out of 27 patients (33%) had MEK-, MTOR-and VEGFinhibition biomarker data from PBMC. Among the nine patients whose PBMC were available for analysis, down-regulation of pERKþ cell frequency was seen in seven (two PR, four SD and one PD). A reduction in circulating endothelial cells was only seen in four (two PR, one SD and one PD) and reduced
Foxp3 þ Treg frequency was detected in seven patients (two PR, four SD and one PD) (supplementary Table S1 , available at Annals of Oncology online).
imaging correlate
Twenty-three out of 27 patients (85%) had at least one DCE-MRI measurement. There was a statistical significant reduction in permeability-surface area product (PS) between baseline and days 7/14. No significant changes in blood flow (F), fractional intravascular space (v1) and fractional interstitial space (v2) changes were noted (supplementary Table S2 , available at Annals of Oncology online). A reduction in PS correlated with inferior PFS and OS (supplementary Tables S3 and S4, available at Annals of Oncology online).
anti-tumour activity
One subject was not evaluable for response as subject only completed one cycle of treatment. Among the 26 patients evaluable Table 2 . Study-drug related adverse events, by dose level and grade Adverse event Overall (n ¼ 27), all grades Sorefenib 400 mg twice daily þ selumetinib 75 mg daily (n ¼ 18)
Sorefenib 400 mg twice daily þ selumetinib 50 mg twice daily (n ¼ 6)
Sorefenib 400 mg twice daily þ selumetinib 100 mg daily (n ¼ 3) 
quality of life
Boxplots of changes of FACT-Hep subscale scores and total scores from baseline over time are shown in supplementary Figure S1 , available at Annals of Oncology online. Patients generally had a decrease in quality of life while on treatment. However, there seemed to be some indication that quality of life improved slightly following the initial drop. The changes in total score were mainly driven by changes in physical well-being, functional well-being and hepatobiliary cancer subscale scores.
discussion
In this phase I study of patients with treatment-naïve advanced HCC, MTD and recommended phase II dose is sorafenib 400 mg bid and selumetinib 75 mg od. This combination demonstrated safety profile consistent with known safety profiles of sorafenib and selumetinib in patients with advanced HCC [2, 14, 15] . While grade 3/4 toxicities include diarrhoea (44%), transaminitis (17%) and hypertension (11%), dose reduction was necessary in only 28%. This compares favourably against combination sorafenib and refametinib (another MEK inhibitor). In this phase II study, rates of grade 3/4 toxicities and SAEs were 81.4% and 42.9%, respectively, culminating in four fatalities. Dose modification was necessary in 90% of the subjects [16] . Admittedly, a high incidence of grade 3/4 diarrhoea (44%) and the finding that 66% of SAEs were GI-related (vomiting/diarrhoea) are testament of overlapping toxicities between sorafenib and selumetinib. The rate of grade 3/4 diarrhoea with sorafenib monotherapy in a phase III study in an Asian population was only 6%. Toxicities and negative trend in QoL are of concern. Patient education and prompt aggressive management strategies could potentially mitigate some of the toxicities in phase II studies.
Sorafenib monotherapy is associated with mPFS and mOS of 5.5 and 10.7 months, respectively, in the SHARP trial. Cheng et al. reported mPFS and mOS of 2.8 and 6.5 months. While direct comparison between both trials and our study is challenging (differences in patient numbers, nature of trial design and dissimilar patient demography), mPFS and mOS of 5.6 and 14.4 months, respectively, achieved with combination sorafenib and selumetib is encouraging. Lack of activity seen with selumetinib monotherapy in a previous study suggests synergistic anti-tumour effect with this combination [14] . The best response in our study was PR in 15% of patients with 48% of experiencing SD with DCR of 63%. Combination sorafenib and refametinib reported a DCR, median PFS and OS of 45%, 4 and 9.5 months, respectively. Intriguingly, three patients with RAS mutations had long durable partial response [16] . We did not detect any RAS mutations among our patients studied (23 patient specimens were available), including our partial responders. original articles Annals of Oncology
